The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
Clinical trial NCT05089123 · COMPLETED
Trial details
- NCT number
- NCT05089123
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-03
- Primary completion
- 2020-05-28
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.